As a pharma technology firm with professional experience spanning so many years, we are collectively accountable to our customers and shareholders by putting science at the heart of everything we do, and to fulfill the mission of constantly focusing on quality and dedicating to continuous research and collaboration with renowned institutes.
In the coming years, World Pharmatech will be focused on growth while ensuring quality innovation and services. The task before us now is to follow through our development plan and implement its objectives. I am confident that with the dedication of our science team and strategic partners, the Company will continue to fulfill its unique and compelling mission of saving and better quality of lives – with excellence and compassion – as we strive to achieve our Vision of a world without health disparities.
President and CEO
Chief Executive Officer, Managing Director
Mr. Wu has been a senior executive with over 40+ years of fortune 500 experiences in the Oil sector having strong capabilities in the execution of global marketing strategies, overseeing manufacturing and operational management. Raised in a family recognized as “Expert in Tumor Surgery” by the World Lung-cancer Alliance and awarded honorary profession by the Roswell Parker Cancer institute, Mr. Wu is a uniquely qualified asset to lead the Company’s Strategic Development activities.
Chief Financial Officer, Managing Director
Before co-founding WPT, Jin worked for eight years in global business consultation as a partner through various international environments, primarily focusing on Healthcare, New Energy, Mining and Media. Prior to that, Jin had served almost 9 years as a corporate controller for Diodes Inc., a public listed semiconductor company based in California. Driven by proficiency, Jin concentrates on team commitment and thought leadership from conception to closing, helping clients with strategic approach to meet their financial targets, as well as building up significant resources in framing and fine-tuning financial structure and go-to-market. Jin is a UH alumnus from TX, and post-graduated in Finance from Pepperdine University, CA.
Science Advisory Board, Managing Director
Dr. Young Wu, a principle investigator at University of California, has performed top quality and high impact research leading his major effort in developing novel anti-cancer drugs for the society. Dr. Wu has a broad background in pharmacology, molecular and cellular biology of diabetes and cancer, and has experiences in research and development of targeted drugs. Currently Dr. Wu is in charge of a scientific R&D project for breast cancer disease, taking high level of responsibility to design, execute and analyze experiments, and participating collaborations with internal and external sector partners.